At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 281 enrolled
Drug / intervention
NVA237 100 µg +2 moredrug
Likely dose
NVA237 100 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Study, to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 2 clinical trial evaluating NVA237 100 µg, Placebo, and 1 other intervention for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 281 participants across 21 sites in 6 countries.
Detailed Summary
This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Netherlands, Spain, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedAug 2, 2007
Enrollment StartAug 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.9 years ago
Interventions
NVA237 100 µgdrug
Dry powder inhalation once a day for up to 28 days
Placebodrug
Placebo to NVA237 dry powder inhalation once a day for up to 28 days
NVA237 200 µgdrug
Dry powder inhalation once a day for up to 28 days